794 related articles for article (PubMed ID: 19420352)
1. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
[TBL] [Abstract][Full Text] [Related]
2. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
3. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
[TBL] [Abstract][Full Text] [Related]
4. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.
Jankowska AM; Szpurka H; Tiu RV; Makishima H; Afable M; Huh J; O'Keefe CL; Ganetzky R; McDevitt MA; Maciejewski JP
Blood; 2009 Jun; 113(25):6403-10. PubMed ID: 19372255
[TBL] [Abstract][Full Text] [Related]
6. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
7. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
8. Tet oncogene family member 2 gene alterations in childhood acute myeloid leukemia.
Li MJ; Yang YL; Lee NC; Jou ST; Lu MY; Chang HH; Lin KH; Peng CT; Lin DT
J Formos Med Assoc; 2016 Sep; 115(9):801-6. PubMed ID: 26414667
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.
Euba B; Vizmanos JL; García-Granero M; Aranaz P; Hurtado C; Migueliz I; Novo FJ; García-Delgado M
Leuk Lymphoma; 2012 Jun; 53(6):1230-3. PubMed ID: 22080757
[No Abstract] [Full Text] [Related]
10. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
[TBL] [Abstract][Full Text] [Related]
11. Expression and prognosis analysis of
Zhang T; Zhao Y; Zhao Y; Zhou J
Aging (Albany NY); 2020 Mar; 12(6):5031-5047. PubMed ID: 32209730
[No Abstract] [Full Text] [Related]
12. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.
Bacher U; Haferlach C; Schnittger S; Kohlmann A; Kern W; Haferlach T
Ann Hematol; 2010 Jul; 89(7):643-52. PubMed ID: 20195608
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
[TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia.
Nabil R; Hassan NM; Abdellateif MS; Gawdat RM; Elshazly SS
Mol Biol Rep; 2023 Jan; 50(1):641-653. PubMed ID: 36371552
[TBL] [Abstract][Full Text] [Related]
16. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.
Kunimoto H; Meydan C; Nazir A; Whitfield J; Shank K; Rapaport F; Maher R; Pronier E; Meyer SC; Garrett-Bakelman FE; Tallman M; Melnick A; Levine RL; Shih AH
Cancer Cell; 2018 Jan; 33(1):44-59.e8. PubMed ID: 29275866
[TBL] [Abstract][Full Text] [Related]
17. [Role of ASXL1 mutation in myeloid malignancies].
Sheng MY; Zhou Y; Xu MJ; Yang FC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
[TBL] [Abstract][Full Text] [Related]
18. Familial myeloid malignancies with germline TET2 mutation.
Duployez N; Goursaud L; Fenwarth L; Bories C; Marceau-Renaut A; Boyer T; Fournier E; Nibourel O; Roche-Lestienne C; Huet G; Beauvais D; Berthon C; Cambier N; Quesnel B; Preudhomme C
Leukemia; 2020 May; 34(5):1450-1453. PubMed ID: 31827242
[No Abstract] [Full Text] [Related]
19. Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases.
Klaus M; Psaraki A; Mastrodemou S; Pyrovolaki K; Mavroudi I; Kalpadakis C; Papadaki HA
Leuk Res; 2011 Mar; 35(3):413-5. PubMed ID: 21087791
[TBL] [Abstract][Full Text] [Related]
20. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.
Yamazaki J; Jelinek J; Lu Y; Cesaroni M; Madzo J; Neumann F; He R; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Kantarjian HM; Liang S; Estecio MR; Godley LA; Issa JP
Cancer Res; 2015 Jul; 75(14):2833-43. PubMed ID: 25972343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
